Efficacy and Biomarker Explanation of AK-112 + Lenvatinib Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC

• Status: Not yet recruiting
• Trial end date: 2024-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aimed to explore the efficacy and biomarker explanation of AK112 combined with Lenvatinib plus platinum based chemotherapy on ALK-rearranged non-small cell lung cancer who failed from first line Alectinib.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hunan Province Tumor Hospital
• Treatments: Lenvatinib

Criteria

Inclusion Criteria:

• Sign written informed consent before implementing any trial-related procedures;

• Patients diagnosed with Lung Adenocarcinoma ALK-Rearranged Stage IIIA-IV by pathology.

• Patients who failed from first line Alectinib with stable brain metastasis included (Radiotherapy treated Oligo-metastasis)

Exclusion Criteria:

• Patients with contraindication of chemotherapy Pregnant or breast feeding women